A new Cancer Cell study reveals an unexpected role for GABA in the tumor microenvironment, and highlights the need for tools that can both visualize and quantify this small immunoregulatory metabolite.

Gamma-aminobutyric acid (GABA) is best known as the major inhibitory neurotransmitter of the central nervous system. A growing body of research shows that its biology extends well beyond neuronal signaling.

A study published in Cancer Cell in 2026, “GABA promotes resistance to immunotherapy in patients with TLS-positive tumors”, identifies tumor-derived GABA as a potential mediator of resistance to immune checkpoint inhibitors (ICIs) in tumors containing tertiary lymphoid structures (TLSs).

The findings extend GABA from neuroscience into tumor immunology and cancer metabolism. They also show why researchers need reliable ways to detect GABA directly in tissues, cells and biological fluids.

Tumor-derived GABA is associated with resistance to immunotherapy

Tertiary lymphoid structures are organized immune-cell aggregates that develop within or around tumors. They have been associated with favorable responses to ICIs in several cancer types.

Yet many patients with TLS-positive tumors do not respond. To understand why, Hernández-Verdin and colleagues, working with teams at the Centre de Recherche des Cordeliers, Institut Bergonié and Gustave Roussy, analyzed clear-cell renal cell carcinoma (ccRCC) and soft-tissue sarcoma (STS) treated with immune checkpoint inhibitors. ImmuSmol and Explicyte scientists Alban Bessède and Jean-Philippe Guégan are co-authors of the study.

In 58 TLS-positive ccRCC tumors from the BIONIKK trial, GABA-related gene signatures were enriched in non-responders. 85% of patients with a high GABA signature did not respond, compared with 26% of those with a low signature. The association was supported in additional ccRCC cohorts (NIVOREN, IMmotion150/151) and in TLS-positive sarcomas from the PEMBROSARC trial. It was seen only in TLS-positive tumors treated with immunotherapy, not in TLS-negative tumors or in patients treated with tyrosine kinase inhibitors.

In ccRCC, GABA production was mainly associated with a population of malignant cells with a proximal-tubule-like phenotype. Nerve-related signatures and nerve density did not explain the association. TLSs located close to these GABA-producing tumor cells showed signs of impaired immune function, including altered B-cell maturation, reduced IgG expression, impaired antigen presentation and increased GABA-receptor expression.

The study therefore suggests that the presence of a TLS is not enough on its own. The metabolic environment around it matters too.

GABA directly affects B-cell function

The investigators then asked whether GABA itself could act on immune cells. In activated human B cells from healthy donors, GABA reduced HLA-DR expression, proliferation and immunoglobulin secretion. The reduction in HLA-DR did not depend on GABA receptors, whereas the effect on B-cell growth was rescued by blocking the GABA_B receptor. This points to both metabolic and receptor-mediated mechanisms.

The pathway was also tested in vivo. In a TLS-positive mouse sarcoma model, the GABA-synthesis inhibitor 3-MPA had no effect on its own but enhanced the antitumor activity of anti-PD-1. Compared with anti-PD-1 alone, the combination increased B-cell density and proliferation inside TLSs, with a trend toward more plasma cells.

Together, these data position GABA as an immunoregulatory metabolite in the tumor microenvironment, not only a neurotransmitter. The authors note that confirmation in patient-derived immune cells and further clinical cohorts will be needed.

Studying GABA requires both spatial and quantitative approaches

The study also measured GABA directly. Intratumoral GABA concentrations, determined by mass spectrometry, correlated inversely with B-cell density inside TLSs. Spatial metabolomics mapped GABA-rich regions around TLSs.

These analyses were combined with transcriptomics and immunophenotyping, which illustrates an important point for GABA research. Expression of GAD1/GAD2, GABA receptors or GABA-related gene signatures describes the pathway, but it does not answer two basic questions:

• Where is GABA itself located?
• How much GABA is present in the sample?

Direct GABA detection complements transcriptomic and enzyme-based approaches. This is where antibody-based imaging and targeted quantitative assays come in.

Direct visualization of GABA with ImmuSmol anti-GABA antibodies

The Cancer Cell study lists the ImmuSmol rabbit polyclonal anti-GABA antibody IS1006 among the reagents in its Key Resources Table.